EU Expected to Approve MS Drug Gilenya

by Kathy Jones on  January 22, 2011 at 9:09 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

In a major relief for multiple sclerosis (MS) patients across the European Union, the European Medicines Agency (EMA) is expected to give its nod for a pill that could be twice as effective as the current injections.
 EU Expected to Approve MS Drug Gilenya
EU Expected to Approve MS Drug Gilenya

While the pill, known as Gilenya which is manufactured by Novartis, is available in the US and Russian markets, the only respite for European MS patients are injections. However the latest recommendation by the EMA will come as a big relief since the pill is not only less painful, but is also more effective than some of the popular injections available to treat the condition.

However the EMA has recommended that the pill should be made available for only those patients suffering from active relapsing-remitting multiple sclerosis (RRMS) or those who fail to respond positively to the interferon beta injection.

"The availability of a tablet to treat the condition will give people more choice and for many will come as a welcome relief from frequent injections", policy and research director of the MS Society, Dr Jayne Spink said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
jainam

How to get this drug for a very needful patient in India?

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive